[Research Report] The Antibody Therapy Market Size is expected to grow from US$ 7,223.2 million in 2022 to US$ 13,879.0 million by 2023; it is estimated to register a CAGR of 7.8% during the forecast period.

Market Insights and Analyst View:

Antibody therapy involves the use of monoclonal antibodies to target specific disease-causing molecules in the body. These monoclonal antibodies can be produced in large quantities and are highly specific, which makes them an attractive option for treating a variety of diseases. Antibody therapy consists of artificial protein that mimics or improves the natural immune system of the body and acts like human antibodies. The antibody therapy market is driven by the increasing prevalence of chronic disorders such as cancer, autoimmune disorders, and others, along with the increase in infectious diseases. Moreover, an increase in product launches and the development of targeted and personalized therapies are further expected to contribute to the growth of the antibody therapies market.

Growth Drivers and Challenges:

Infectious diseases are rapidly increasing across the world. The World Health Organization (WHO) reported that infectious diseases are likely to cause over 30 million deaths each year. According to a new report by TB Facts Org, ~10.6 million people were diagnosed with tuberculosis (TB) in 2021, which has increased by 4.5% from 10.1 million in 2020 globally. Additionally, the ease of international travel has led to an additional layer of complexity in terms of tackling infectious diseases, which led to the pandemic conditions. Moreover, changing climatic conditions on a global level have contributed to the prevalence of infectious diseases as it can increase the severity of the infectious diseases. As per the United Nations Office for Disaster Risk Reduction (UNDDR), climate change can intensify the infectious diseases encountered by humans on the global level by 58%.

Since the 1970s, about 40 infectious diseases have been discovered, including SARS, MERS, Ebola virus disease, chikungunya, avian flu, swine flu, zika virus infection, and most recently, COVID-19. As per the CDC, between September 2020 and May 2021, 1,675 of 818,939 respiratory specimens tested by US clinical laboratories were positive for an influenza virus in the US. Moreover, the growing aging population and changes in social behavior and lifestyle contribute to some of the common long-term health conditions. As per the World Health Organization (WHO), the prevalence of chronic lifestyle diseases is expected to increase by 57% by the end of 2026. The emerging markets will be hit hardest, as a population explosion is expected in developing countries. With the increasing urbanization, people are more inclined toward a sedentary lifestyle, which results in rheumatoid arthritis, diabetes, and others. Diabetes is one of the major global health issues of the 21st century. According to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to reach 62 million by 2045. The increase in disease prevalence is approximated to be 35% during the projection period. Therefore, an increase in infectious and chronic disorders on a global level is expected to drive the growth of the antibody therapy market.

However, the availability of antibody therapy in limited specific regions or countries, mostly including developed regions, makes it difficult to access some patients from developing economies. Additionally, the high cost associated with its development has increased the prices of antibody therapy along with associated side effects, which are expected to hamper the antibody therapy market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Antibody Therapy Market: Strategic Insights

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The "Global Antibody Therapy Market Size" is segmented based on type, end-user, and geography. Based on type, the antibody therapy market is bifurcated into monoclonal antibodies and antibody-drug conjugates. The monoclonal antibodies segment is further classified into oncology, autoimmune disease, infectious disease, and others. Based on end users, the antibody therapy market is segmented into hospitals, specialty centers, and others. The antibody therapy market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

Based on type, the antibody therapy market size is bifurcated into monoclonal antibodies and antibody-drug conjugates. Further, the monoclonal antibodies are segmented into oncology, autoimmune disease, infectious disease, and others. In 2022, the monoclonal antibodies segment held the largest share of the market. It was anticipated to grow at a higher CAGR during the coming years owing to the increasing application areas, including cancer, autoimmune disorders, infectious diseases, and others. Monoclonal antibodies are designed to target specific proteins or cells in the body as they are exact and can be tailored to target specific diseases. Monoclonal antibodies have been used to treat a range of conditions, including cancer, autoimmune disease, and infectious disease.

Moreover, the increasing prevalence of cancer, infectious diseases, autoimmune disorders, and others are expected to contribute to the overall market growth. For instance, according to WHO, there were ~19 million new cancer cases reported globally during 2020. Additionally, according to the Centers for Disease Control and Prevention (CDC), ~10.2 million people visit physician offices for the treatment of infectious and parasitic diseases in African countries every year. Monoclonal antibody-based therapies have various advantages, including high specificity, reduced side effects, and an easy manufacturing process that can lead to manufacturing in large quantities. There are various monoclonal antibody-based therapies available in the market, including Herceptin for breast cancer, Rituxan for non-Hodgkin’s lymphoma, and Keytruda for different types of cancer. Apart from these, various monoclonal-based antibodies are in development and are expected to launch in the near future, contributing to the growth of the antibody therapy market.

Based on the end user, the antibody therapy market is segmented into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share of the market, and it is anticipated to register the highest CAGR during the forecast period. Hospitals are one of the most preferred healthcare organizations for treatment. Antibody therapies are typically administered through intravenous infusion or injections, with patients receiving regular doses over weeks or months. Hospitals often have specialized infusion centers or clinics that are dedicated to providing antibody therapy to the patient population. Moreover, the increasing number of hospitals, other healthcare facilities, and healthcare infrastructure, along with easy accessibility and availability of hospitals to the large population globally, is expected to drive the hospital segment growth. Furthermore, the availability of different specialists and services under one roof, followed by advanced therapies and post-treatment care, is also expected to promote the growth of the antibody therapy market.

Regional Analysis:

Based on geography, the antibody therapy market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2022, North America held the largest antibody therapy market share, closely followed by Europe, and Asia Pacific is estimated to register the highest CAGR during the forecast period. The growth of the North American market is primarily driven by the increasing prevalence of chronic and infectious diseases, followed by the presence of significant market players in the region. As per the National MS Society, there were ~1 million people in the US living with multiple sclerosis in 2022. The manufacturers from the region are involved in the research and development activities of antibody therapies, which can be used in the treatment of various conditions, including cancer, autoimmune disorders, and others. The increase in research activities led to innovation, new product launches, product approvals, and others, which are expected to drive the growth of the antibody therapy market. The US is one of the developed countries of North America region, accounting for the major market, and is expected to develop moderately over the forecast period.

Furthermore, an increase in strategic collaboration among various market players for the development of antibody therapies is expected to support the antibody therapy market growth. For instance, in March 2020, AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for the treatment and prevention of COVID-19. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing, and distribution of therapeutic antibodies.

However, Asia Pacific registered as the fastest-growing region in the global antibody therapy market. The market in this region is expected to grow significantly in countries such as China, Japan, and India. The market's growth is attributed to the increasing focus of market players in developing economies and the increasing prevalence of chronic and infectious diseases, followed by the increasing use of antibody-based biologics. Moreover, an increase in research and development activities in the region led to the development of new products to support product launches in the region. For instance, in July 2022, Brii Biosciences Limited and TSB Therapeutics (Beijing) Co., Ltd launched amubarvimab/romlusevimab combination, a long-acting COVID-19 neutralizing antibody therapy, in China. On July 7, the first commercial batch of the antibodies was released, marking an important milestone in the commercialization of the combination therapy. Moreover, an increase in healthcare expenditure and growing demand for targeted therapies in countries such as India, China, and Japan are expected to amplify the market growth.

Japan has a well-established healthcare system followed by a high prevalence of cancer, establishing it as the key country for antibody therapy. Additionally, India and China have large populations, which is expected to increase the demand for advanced healthcare treatments, including antibody therapy. In addition, the region has a presence of a few key market players, including Bristol-Myers Squibb, Merck & Co, Novartis, and others investing heavily in research and development focusing on the development of new antibody therapies and their expansion in the region as it offers ample growth opportunities. Therefore, all the factors mentioned above are expected to drive the growth of the antibody therapy market in the near future.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global antibody therapy market are listed below:

1. In September 2023, The University of Texas MD Anderson Cancer Center and Panacea Venture announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.

2. In March 2022, Sanofi and SeagenInc. Collaborated to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein, and Sanofi currently has one ADC in development.

3. In January 2022, Fate Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate. The Company plans to initiate a clinical investigation of FT536 as a monotherapy and in combination with tumor-targeting monoclonal antibody therapy for the treatment of multiple solid tumor indications.

4. In July 2020, AstraZeneca entered into a new global development and commercialization agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) and potential new medicine for the treatment of multiple tumor types.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global antibody therapy market include Merck & Co. Inc, Eli Lilly and Company, Seagen, Novartis AG, Takeda Pharmaceuticals, Bristol-Myers Squibb, Johnson & Jhonson, AstraZeneca, Regeneron Pharmaceuticals Inc, Amgen, among others. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers and subsequently increases their market share.